Stenosis of lacrimal punctum

Summary

Stenosis of lacrimal punctum (MONDO:0001767) is a disease. A subtype of lacrimal apparatus disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	stenosis of lacrimal punctum
Mondo ID	MONDO:0001767
DOID	DOID:13653
ICD-10-CM	H04.56
SNOMED CT	74783009
UMLS	C0155244
MedGen	509869
Anatomy (UBERON)	UBERON:0010284
Is cancer (heuristic)	no

Disease family

This is a subtype of lacrimal apparatus disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › lacrimal apparatus disorder › stenosis of lacrimal punctum

Related subtypes (16): lacrimal passage granuloma, eversion of lacrimal punctum, stenosis of lacrimal passage, excessive tearing, primary lacrimal atrophy, secondary lacrimal atrophy, lacrimal system cancer, stenosis of lacrimal sac, acute inflammation of lacrimal passage, chronic inflammation of lacrimal passage, dry eye syndrome, IgG4-related dacryoadenitis and sialadenitis, isolated congenital alacrima, disorder of lacrimal gland, nasolacrimal duct disorder, syndromic lacrimal system disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.